An examination of Selank’s proposed immunomodulatory and neuroplasticity mechanisms, including IL-6 cytokine modulation, BDNF induction patterns in rodent models, and the enkephalin peptidase inhibition hypothesis.

A research-context examination of selank and gabaergic modulation: indirect gaba-a receptor pathway effects and enkephalin peptidase inhibition in rodent anxiety models, analyzing preclinical molecular evidence and known translational limitations.

Analysing Selank’s impact on IFN-gamma and IL-6 expression in splenic leukocyte cultures under acute stress models.

This article investigates Selank’s modulation of the GABAergic system and GABA-A receptor conductance dynamics in preclinical models.

An analysis of Selank’s cytokine-regulating properties in rodent stress models, covering IL-1beta, IL-6, and TGF-beta1 modulation in a social stress paradigm.

An in-depth look at Selank’s preclinical pharmacology across serotonin, GABA, and neurotrophin pathways, with attention to study limitations and the translational evidence gap.

Preclinical research overview of Selank’s GABA-A allosteric modulation, enkephalin degradation enzyme inhibition, and serotonin turnover in anxiety and stress rodent models.

This article examines preclinical research on Selank’s influence on GABAergic gene expression in rodent frontal cortex, including findings from neurotransmission transcriptome studies and proposed allosteric modulation mechanisms distinguishing it from direct benzodiazepine-site agonists.

Selank is a synthetic heptapeptide studied for its competitive inhibition of enkephalin-degrading enzymes and BDNF/TrkB signaling modulation in preclinical anxiety research models.

A research-context analysis of Selank examining GABA-A receptor allosteric modulation, frontal cortex gene expression profiling, and the distinction from benzodiazepine site agonism in preclinical models.